Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO®]

Drugs

Volumn 69, Issue 1, 2009, Pages 115-122

  Duggan, Sean T ^a,b   Plosker, Greg L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; JENCE VAC; UNCLASSIFIED DRUG;

ANTIBODY TITER; CLINICAL TRIAL; CYSTITIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS A; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE HARDENING; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; MYALGIA; NAUSEA; REVIEW; RHINOPHARYNGITIS; SEROCONVERSION;

ADULT; ANIMALS; CERCOPITHECUS AETHIOPS; CHILD; CLINICAL TRIALS AS TOPIC; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; TIME FACTORS; VERO CELLS;

FLAVIVIRUS; IXODIDA; JAPANESE ENCEPHALITIS VIRUS;

EID: 59749104655     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969010-00008     Document Type: Review

References (21)

1. Centers for Disease Control and Prevention. Travelers' health: yellow book. Chapter 4. Prevention of specific infectious diseases: Japanese encephalitis [online]. Available from URL: http://wwwn.cdc.gov/travel/ yellowBookCh4-JapaneseEncephalitis.aspx [Accessed 2008 Sep 29]
2. Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1993; 42 (RR-01): 1-15
3. World Health Organization. Japanese encephalitis vaccines. Weekly epidemiological record 2006; 81, 34/35: 331-340 [online]. Available from URL: http://www.who.int/wer/2006/wer8134-35.pdf [Accessed 2008 Sep 1]
4. Gould E, Solomon T. Pathogenic flaviviruses. Lancet 2008; 371 (9611): 500-9
5. Solomon T. Control of Japanese encephalitis: within our grasp? N Engl J Med 2006; 355 (9): 869-71
6. Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol 2002; 267: 105-38
7. Sakaguchi M, Nakashima K, Takahashi H, et al. Anaphylaxis to Japanese encephalitis vaccine. Allergy 2001; 56 (8): 804-5
8. Sugawara K, Nishiyama K, Ishikawa Y, et al. Development of vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 2002 Dec; 30 (4): 303-14
9. Lehner C, Eder G, Formica A, et al. Safety and immunogenicity of concomitant vaccination with IC51 and hepatitis A vaccine in healthy subjects: a single-blind randomized controlled phase 3 study [abstract no. 122]. 56th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2007 Nov 4-8; New Orleans (LA), 36
10. Schuller E, Klade CS, Wölfl G, et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled phase 3 study. Vaccine. In press
11. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008 Aug 12; 26 (34): 4382-6
12. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007 Dec 1; 370 (9602): 1847-53
13. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the novel, vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51. Vaccine 2008 Sep 17; 26 (48): 6151-6
14. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008 Aug 15; 198 (4): 493-9
15. Schuller E, Kishore TSA, Klade C, et al. First clinical trial of a vero cell derived, inactivated Japanese encephalitis (JE) vaccine IC51 in pediatric population [abstract]. 57th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2008 Dec 7-11; New Orleans (LA)
16. Mueller Z. First clinical trial of a vero cell derived, inactivated Japanese encephalitis vaccine IC51 in pediatric population [oral presentation]. 57th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2008 Dec 7-11; New Orleans (LA) [online]. Available from URL: http://www.intercell.com/fileadmin/user-upload/beginners/News/2008-ENG/ 2008-12-10-Presentation-ASTMH.pdf [Accessed 2009 Jan 1]
17. Japanese Encephalitis Virus Vaccine Inactivated (JE-Vax): US prescribing information. Swiftwater (PA): Sanofi Pasteur, 2005 [online]. Available from URL: http://www.fda.gov/cber/label/jevaxLB.pdf [Accessed 2008 Sep 23]
18. Ferguson M, Kurane I, Wimalaratne O, et al. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 2007 Jul 20; 25 (29): 5233-43
19. Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005; 23 (45): 5205-11
20. Dubischar-Kastner K, Kaltenboeck A, Schuller E, et al. Six months safety of a vero-cell culture derived Japanese encephalitis vaccine, IXIARO®, IC51, across phase 3 trials and in a long-term follow-up cohort [abstract]. 57th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2008 Dec 7-11; New Orleans (LA)
21. Committee for medicinal products for human use summary of positive opinion for IXIARO® [online]. Available from URL: http://www.emea.europa.eu/ pdfs/human/opinion/Ixiaro-66231608en.pdf [Accessed 2009 Jan 6]